Daratumumab (DARA) + lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): An updated subgroup analysis of GRIFFIN Meeting Abstract
| Authors: | Nooka, A.; Kaufman, J.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y.; Reeves, B.; Wildes, T.; Holstein, S.; Anderson, L.; Badros, A.; Shune, L.; Chari, A.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T.; Usmani, S.; Richardson, P.; Voorhees, P. |
| Abstract Title: | Daratumumab (DARA) + lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): An updated subgroup analysis of GRIFFIN |
| Meeting Title: | 19th International Myeloma Society Annual Meeting (IMS) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. |
| Meeting Dates: | 2022 Aug 25-27 |
| Meeting Location: | Los Angeles, CA |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-08-01 |
| Start Page: | S155 |
| End Page: | S156 |
| Language: | English |
| ACCESSION: | WOS:000895909200275 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(22)00549-3 |
| Notes: | Meeting Abstract: P-219 -- Source: Wos |
